ASSOCIATION BETWEEN CARDIOTOXICITY RISK AND ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS SUBMITTED TO ANTHRACYCLINE CHEMOTHERAPY.
cardiotoxicity; anthracycline; electrocardiogram; QTc; global longitudinal strain; GLS.
Introduction: Anthracycline chemotherapy treatment is associated with cardiotoxicity. Echocardiography is a useful tool in the detection of early myocardial injury. The electrocardiogram still has no established role in this scenario. Objective: To analyze the association between electrocardiographic changes and the development of subclinical cardiotoxicity in cancer patients undergoing treatment with anthracycline. Methods: Prospective cohort of cancer patients treated with anthracycline. Transthoracic echocardiograms with global longitudinal strain and electrocardiogram were performed before the start of treatment, at 3 and 6 months of follow-up to assess the presence or absence of subclinical cardiotoxicity, defined by a relative drop in global longitudinal strain greater than 15% in relation to the initial measurement. on at least one echocardiogram. Fisher's exact test was applied to assess this association. Results: Of the 33 patients included (mean age = 49 ± 9.5 years), 23 had breast cancer. Eight (24.24%) had incipient cardiotoxicity. QTc in women was higher than baseline at 6 months by both Bazett and Fridericia (p = 0.011 and p =0.038, respectively). There was an association, in women, between QTc > 460ms (corrected by Bazett) at 3 months and a drop in global longitudinal strain >15% in this period (p=0.043). Conclusion: The presence of QTc > 460ms at 3 months in women was associated with subclinical cardiotoxicity.